PURPOSE: To assess the quality of life in a group of rectal cancer patients during the treatment period. MATERIAL AND METHODS: A sample of 83 rectal cancer patients in Dukes' stages B2 or C who started a chemoradiotherapy treatment followed by surgery, have filled in the EORTC core questionnaire QLQC30 and the colorectal module QLQ-CR38, in three moments during the treatment and follow-up periods: at the beginning of the treatment, at the end of the chemoradiotherapy, and after surgery. Clinical and demographic data have also been recorded. Quality of Life scores and changes in them among the three assessments have been calculated. RESULTS: Quality of life scores of patients who have followed the treatment has been good in most dimensions, and has shown similar to the clinical data. Soft and moderate alterations have appeared in the areas of disease symptoms, treatment toxicity, fatigue, emotional and sexual functioning, and also in functional areas after surgery. Quality of life has been stable or has had small changes in most dimensions. A worsening in toxicity areas has appeared after the neoadyuvant treatment. After surgery there has been a worsening in functional areas, fatigue and appetite loss, and an improvement in diarrhoea. CONCLUSIONS: Quality of life scores and clinical data indicate that the situation of the patients who have received the treatments has been good. Patients under treatment stood it adequately.
PURPOSE: To assess the quality of life in a group of rectal cancerpatients during the treatment period. MATERIAL AND METHODS: A sample of 83 rectal cancerpatients in Dukes' stages B2 or C who started a chemoradiotherapy treatment followed by surgery, have filled in the EORTC core questionnaire QLQC30 and the colorectal module QLQ-CR38, in three moments during the treatment and follow-up periods: at the beginning of the treatment, at the end of the chemoradiotherapy, and after surgery. Clinical and demographic data have also been recorded. Quality of Life scores and changes in them among the three assessments have been calculated. RESULTS: Quality of life scores of patients who have followed the treatment has been good in most dimensions, and has shown similar to the clinical data. Soft and moderate alterations have appeared in the areas of disease symptoms, treatment toxicity, fatigue, emotional and sexual functioning, and also in functional areas after surgery. Quality of life has been stable or has had small changes in most dimensions. A worsening in toxicity areas has appeared after the neoadyuvant treatment. After surgery there has been a worsening in functional areas, fatigue and appetite loss, and an improvement in diarrhoea. CONCLUSIONS: Quality of life scores and clinical data indicate that the situation of the patients who have received the treatments has been good. Patients under treatment stood it adequately.
Authors: R Sauer; R Fietkau; C Wittekind; P Martus; C Rödel; W Hohenberger; G Jatzko; H Sabitzer; J H Karstens; H Becker; C Hess; R Raab Journal: Strahlenther Onkol Date: 2001-04 Impact factor: 3.621
Authors: Abdelkarim S Allal; Pascal Gervaz; Philippe Gertsch; Jacques Bernier; Arnaud D Roth; Philippe Morel; Sabine Bieri Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: D Korolija; S Sauerland; S Wood-Dauphinée; C C Abbou; E Eypasch; M García Caballero; M A Lumsden; B Millat; J R T Monson; G Nilsson; R Pointner; W Schwenk; A Shamiyeh; A Szold; E Targarona; B Ure; E Neugebauer Journal: Surg Endosc Date: 2004-04-27 Impact factor: 4.584
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: R Sauer; R Fietkau; C Wittekind; C Rödel; P Martus; W Hohenberger; J Tschmelitsch; H Sabitzer; J-H Karstens; H Becker; C Hess; R Raab Journal: Colorectal Dis Date: 2003-09 Impact factor: 3.788
Authors: Juan Ignacio Arraras; Javier Suárez; Fernando Arias de la Vega; Ruth Vera; Gemma Asín; Virginia Arrazubi; Mikel Rico; Lucía Teijeira; Jaione Azparren Journal: Clin Transl Oncol Date: 2011-01 Impact factor: 3.405
Authors: X Serra-Aracil; C Pericay; T Golda; L Mora; E Targarona; S Delgado; A Reina; F Vallribera; J M Enriquez-Navascues; S Serra-Pla; J C Garcia-Pacheco Journal: Int J Colorectal Dis Date: 2017-12-12 Impact factor: 2.571
Authors: J I Arraras; E Villafranca; F Arias de la Vega; P Romero; M Rico; M Vila; G Asín; V Chicata; M A Domínguez; N Lainez; A Manterola; E Martínez; M Martínez Journal: Clin Transl Oncol Date: 2009-03 Impact factor: 3.405